Institute for International Research

This one-of-a-kind conference offered insights from leading companies about how they plan to build the capabilities to capitalize on the entire landscape of biologic products and technologies. From innovative biologics to biobetters to biosimilars, attendees learned how they planned their growth strategies to bring new products to market more quickly.

This conference is the only biologics conference on the market to discuss business strategies and market opportunities for both innovators and generics companies alike. Whether you are interested in building a business in innovative biologics, biobetters or biosimilars or protecting your innovations from upcoming patent expirations and competitor products, this must-attend conference provides you with numerous strategies and concrete ideas from industryleading companies and emerging players in this burgeoning field.

In the following sessions, over 25 speakers provided information on:

• Strategies and business models to de-risk biologics drug development and develop a competitive edge
• Development strategies for biobetters and improved versions of existing biologics
• How to build technology capabilities as a strategy to share in the growing biologics market
• The evolving market landscape of biosimilars
• Regulatory and commercial experiences of approved biosimilars in different markets
• Global experiences in biosimilar development: translating success to the US and Europe